Advertisement

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Feb
15
Today In Oncology
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
Oncolytic Virus Triggers Immune System Against Glioblastoma Cells
Adjuvant Durvalumab in Resected Early-Stage NSCLC
FDA Approves Labeling Changes to Menopausal Hormone Therapy Products
Young-Onset Pancreatic Cancer Can Alcohol Consumption Raise Risk
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo